Zhao Yilin, Zhu Dan
The Departments of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Department of Cardiology, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology & Regulatory Peptides, Ministry of Health & Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing 100191, China.
Biomark Med. 2016 Aug;10(8):877-88. doi: 10.2217/bmm-2016-0086. Epub 2016 Jul 14.
Catestatin (CST) was first named in 1997 for its catecholamine-inhibitory activity. It was discovered as a potent inhibitor of catecholamine secretion and as a regulator of histamine release. Accumulating evidence shows that CST is involved with cardiovascular diseases; however, whether CST is a protective factor for these conditions and the mechanisms by which such actions may be mediated are not well understood. In this article, we review recent basic research and clinical trials in the study of CST and summarize the association of CST with cardiovascular diseases. We review data obtained from MedLine via PubMed and from our own investigations.
癌抑素（CST）于1997年首次因其儿茶酚胺抑制活性而得名。它被发现是儿茶酚胺分泌的强效抑制剂和组胺释放的调节剂。越来越多的证据表明，CST与心血管疾病有关；然而，CST是否是这些疾病的保护因素以及介导这些作用的机制尚不清楚。在本文中，我们回顾了CST研究方面最近的基础研究和临床试验，并总结了CST与心血管疾病的关联。我们回顾了通过PubMed从MedLine以及我们自己的研究中获得的数据。
